From the Editor

Apr 01, 2013
Pharmaceutical Executive
The conversation thread that binds this month's Pharm Exec is building communities—when the harsh economics of market change suddenly discounts the familiar, then the best way to move up is to reach out.
Mar 01, 2013
Pharmaceutical Executive
Pharm Exec's 35-member Editorial Advisory Board met last month to discuss a range of topics, including the influence of other business sectors on pharma's global strategy.
Feb 01, 2013
Pharmaceutical Executive
Today's most important public health story is the advance in our understanding of the biology of cancer, writes Pharm Exec Editor-in-Chief William Looney.
Jan 01, 2013
Pharmaceutical Executive
2013 may be a number associated with the fate of the luckless, but our annual review of the business and policy environment for Big Pharma suggests otherwise—as we near the midway point in the "tween" decade, there is good fortune in store for those with the perspective that comes with the long view.
Dec 01, 2012
Pharmaceutical Executive
The calendar says its wrap-up time, not just for gifts but for some of the trends that shaped the industry—for good or bad—in 2012.
Nov 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Spain's leading business school, IESE, organized an expert conference on October 2-3 to address two simple questions. First, how can providers and payers work together to generate more value from existing resources? Second, what must be done to ensure the system continues to create value in the first place?
Oct 01, 2012
Pharmaceutical Executive
Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. Solving the puzzle correctly—with a new product as the sum of its parts—depends on making that lengthy progression from basic science to registration as linear as possible.
Sep 01, 2012
Pharmaceutical Executive
Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.
Aug 01, 2012
Pharmaceutical Executive
This month's feature by Ben Comer highlights what's behind the new Corporate Integrity Agreement (CIA) imposed on GSK by theHHS Office of Inspector-General to compensate for a long list of marketing and pricing malfeasances
Jul 01, 2012
Pharmaceutical Executive
Pharm Exec's 2012 roster of Emerging Leaders—our sixth to date—is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.
lorem ipsum